« Back to Record
Citation APA

Aftimos, P., Rolfo, C., Rottey, S., Barthélémy, P., Borg, C., Park, K., Oh, D. Y., Kim, S. W., De Jonge, N., Hanssens, V., Zwanenpoel, K., Molthoff, C., Vugts, D., Dreier, T., Verheesen, P., van Dongen, G. A. M. S., Jacobs, J., Van Rompaey, L., Hultberg, A., Michieli, P., Pauwels, P., Fung, S., Thibault, A., De Haard, H., Leupin, N., & Awada, A. (2021). The nhance® mutation-equipped anti-met antibody argx-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients. Biomedicines, 9(6), 665. doi:10.3390/biomedicines9060665


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/328621

Aftimos, P., Rolfo, C., Rottey, S., Barthélémy, P., Borg, C., Park, K., Oh, D. Y., Kim, S. W., De Jonge, N., Hanssens, V., Zwanenpoel, K., Molthoff, C., Vugts, D., Dreier, T., Verheesen, P., van Dongen, G. A. M. S., Jacobs, J., Van Rompaey, L., Hultberg, A., Michieli, P., Pauwels, P., Fung, S., Thibault, A., De Haard, H., Leupin, N., & Awada, A. (2021). The nhance® mutation-equipped anti-met antibody argx-111 displays increased tissue penetration and anti-tumor activity in advanced cancer patients. Biomedicines, 9(6), 665. doi:10.3390/biomedicines9060665